B6 - Scientific and technological advances – Learn, adapt, employ to optimize patient wellness and safety

Auditorium 2

Organised by the FIP Programme Committee in collaboration with FIP’s Community Pharmacy Section

Chairs

Ralph Altiere, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, USA and Hiroshi Suzuki, University of Tokyo Hospital, Japan

Introduction

Advances in science and technology will accelerate in the years ahead enabling pharmacists to expand and enhance their role in the pharmaceutical care of patients. We have emerging capabilities today, by examining mutations of a tumor genome followed by analysis of big data using AI-based technology, to discover new drug targets that allow for each patient to receive personalized pharmacotherapy based on the genome sequence of their cancer. Continued research advances will expand these capabilities to multiple forms of cancer and other disease states, greatly enhancing effectiveness of therapeutic modalities. Technological advances also are making it possible to self-monitor physiologic functions and health status to support wellness and disease prevention and to provide real-time data to health professionals for early intervention when needed whether through in person visits or digital means such as telemedicine. Although such developments in science and technology are associated with the possibility to greatly advance pharmaceutical care of patients, many challenges exist including analysis of vast amounts of data requiring greater use of AI technologies to assist health professionals in diagnosis, decision-making and design and use of precision therapeutic treatments. Regulatory challenges may be even greater, balancing patient safety along with supporting rapid innovation and implementation. Pharmacists, who will be at the forefront of discovery, deployment and use of these new technologies to assist patients in living a healthier life, will have the challenge of maintaining knowledge and expertise in these emerging and continual innovations.

Programme

  1. Accelerated drug discovery and development including biomarker identification, drug design, PKPD predictive modelling in clinical trial design
    Don Mager, University at Buffalo, USA
  2. Personal health devices and AI applications in guiding diagnosis and application of precision medicine, personalized healthcare
    James Mault, CQuentia, USA
  3. Education and training of students and practitioners about advanced technologies impacting healthcare
    Clive Roberts, University of Nottingham, UK
  4. Regulatory challenges – Balancing patient safety along with supporting rapid innovation and implementation
    Nikolai Bruns, Danish Medicines Agency and European Medicines Agency, Denmark

Learning Objectives

At the end of this session, participants will be able to:

1. Describe scientific advances that will impact health care delivery and effectiveness
2. Identify how personal health devices and AI can be used to personalize health care
3. Define education and training needs to enable pharmacists to develop mastery of these advances to provide the best care for patients
4. Describe the challenges of balancing regulatory actions that promote innovation while guarding patient safety

Type of session: Knowledge-based